Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow-to-Debt Ratio
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of ₩2.62 Billion could theoretically repay 0% of its total liabilities (₩18.23 Billion) in one year. See cash generation quality of Sinil Pharmaceutical Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Also explore 012790 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Sinil Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see how much is Sinil Pharmaceutical Co. Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.17x | ₩22.69 Billion | ₩19.36 Billion | ▲ +35.9% |
| 2023 | 0.86x | ₩15.15 Billion | ₩17.56 Billion | ▲ +23.3% |
| 2022 | 0.70x | ₩13.69 Billion | ₩19.55 Billion | ▼ -1.1% |
| 2021 | 0.71x | ₩11.16 Billion | ₩15.78 Billion | ▲ +10.8% |
| 2020 | 0.64x | ₩11.06 Billion | ₩17.33 Billion | ▼ -13.9% |
| 2019 | 0.74x | ₩12.31 Billion | ₩16.59 Billion | ▼ -9.5% |
| 2018 | 0.82x | ₩9.19 Billion | ₩11.22 Billion | ▲ +9.5% |
| 2017 | 0.75x | ₩8.67 Billion | ₩11.59 Billion | ▼ -32.8% |
| 2016 | 1.11x | ₩12.09 Billion | ₩10.86 Billion | ▲ +5.8% |
| 2015 | 1.05x | ₩9.56 Billion | ₩9.09 Billion | ▲ +2.1% |
| 2014 | 1.03x | ₩9.33 Billion | ₩9.06 Billion | — |